Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Cancer Immunol Res. 2017 Feb 21;5(4):300–311. doi: 10.1158/2326-6066.CIR-16-0234

Fig. 3. NKG2D ligands are induced by IL12 plus doxorubicin in a human melanoma xenograft model.

Fig. 3

Mel 2549 tumor-bearing NSG mice (n = 3) were treated twice (10 days apart) with one of the four indicated treatments. 5 million autologous TILs were infused the days after each treatment. Tumors were collected on day 4 after the second treatment. (A) Flow cytometry analyses of NKG2D ligands MICA (top) and ULBP2 (bottom). Bar graphs show the normalized mean fluorescence index (MFI of NKG2D ligands minus MFI of isotype control). (B) Immunoblots of MICA and ULBP2 in tumor samples from mice receiving one of the four indicated treatments. Intensity quantification (intensity of Rae-1/intensity of β-Actin) shown under each blot represents the mean intensity of three repeated experiments. (C) Tumor size was measured from 7 days after inoculation twice weekly. Black arrows represent treatment dates. Red arrows represent TIL infusion dates.